![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 19, 2023
This randomized phase 2 study is assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer
October 19, 2023
These four leukemia treatment trials and an observational study of myelodysplastic syndromes are all open and enrolling patients
August 25, 2023
This phase 3 study of oligometastatic head and neck cancer is exploring whether it is more effective to add radiation therapy to standard immunotherapy in patients with stable disease after initial chemotherapy plus immunotherapy
August 25, 2023
The ECOG-ACRIN Sarcoma Working Group has launched its first trial, an international collaboration to evaluate chemotherapy prior to surgery in patients with retroperitoneal leiomyosarcoma or dedifferentiated liposarcoma
August 25, 2023
The changes broaden eligibility for prostate cancer patients and make baseline scanning easier for sites in this phase 3 trial using PET imaging to guide treatment for recurrence
August 25, 2023
The GIANT trial (EA2186) is the first randomized clinical trial to focus on vulnerable older adults with treatment-naïve metastatic pancreatic cancer who are not candidates for standard therapy.
June 30, 2023
This phase 2 trial is testing how well FDG-PET/CT imaging can predict response to standard-of-care neoadjuvant therapy in patients with HER2-positive breast cancer
June 30, 2023
This phase 2 trial is evaluating the activity of nilotinib-paclitaxel in patients with solid tumors and exploring predictive biomarkers of response and resistance
June 30, 2023
This phase 3 study aims to determine the optimal sequencing of surgery, chemotherapy, and chemoradiotherapy for patients with cancer of the penis
June 30, 2023
Researchers presented numerous research abstracts and trial updates at the 2023 ASCO Annual Meeting
April 19, 2023
ComboMATCH researchers are discovering new drug combinations that show promise for patients with advanced cancers, based on strong pre-clinical in vivo evidence of therapeutic effectiveness
April 19, 2023
This phase 2 study is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes